Detail akcie Charles River Lb online

Business Summary: Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Financial Summary: BRIEF: For the fiscal year ended 30 December 2023, Charles River Lbrtrs ntrntl Inc revenues increased 4% to $4.13B. Net income decreased 2% to $474.6M. Revenues reflect Discovery And Safety Assessment segment increase of 7% to $2.62B, Research Models segment increase of 7% to $792.3M, Canada segment increase of 22% to $487.3M, Europe segment increase of 4% to $1.08B, Asia Pacific (Region) segment increase of 4% to $200.8M.